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Complement activation contributes directly to health
and disease. It neutralizes pathogens and stimulates
immune processes. Defects lead to immunodefi-
ciency and autoimmune diseases, whereas inappro-
priate activation causes self-damage. In the lectin
and classical pathways, complement is triggered
upon recognition of a pathogen by an activating
complex. Here we present the first structure of
such a complex in the form of the collagen-like do-
main of mannan-binding lectin (MBL) and the binding
domain of its associated protease (MASP-1/-3). The
collagen binds within a groove using a pivotal lysine
side chain that interacts with Ca2+-coordinating resi-
dues, revealing the essential role of Ca2+. This mode
of binding is prototypic for all activating complexes
of the lectin and classical pathways, and suggests
a general mechanism for the global changes that
drive activation. The structural insights reveal a new
focus for inhibitors and we have validated this con-
cept by targeting the binding pocket of the MASP.
INTRODUCTION
The lectin pathway of complement provides primary protection
against invading pathogens. It is initiated by mannan-binding
lectin (MBL) or serum ficolins, which bind to carbohydrates on
pathogens to activate MBL-associated serine proteases
(MASPs), leading to complement-induced lysis and stimulation
of inflammatory and adaptive immune responses (Schwaeble
et al., 2002). Common polymorphisms in MBL and MASPs
lead to immunodeficiencies (Garred et al., 1997; Neth et al.,
2001; Sumiya et al., 1991), increased severity of inflammatory
disorders (Kilpatrick, 2002), and are risk factors in a number of
clinical settings (Mullighan et al., 2008). Recent studies have
shown that inhibition of the lectin pathway confers considerable
protection toward myocardial and gastrointestinal ischemia/
reperfusion injury (Schwaeble et al., 2011), so selective inhibitors
will provide important therapeutic benefits.
MBLs and ficolins have bouquet-like structures formed of
collagen-like stems that are linked at one end (the base) andStructure 19, 1635–16splay apart at the other to terminate in clusters of pathogen-
recognition domains (Drickamer and Taylor, 1993; Fujita
et al., 2004). They circulate as complexes with three different
zymogen MASPs (MASP-1 to -3) that autoactivate upon binding
to pathogen-associated molecular patterns. MASPs recognize
a short motif in the collagen-like stems of MBL, comprising
OGKXGP (see Figure S1 available online), where the lysine is
essential, O is hydroxyproline, and X is generally an aliphatic
or methionine residue (Girija et al., 2007; Wallis et al., 2004).
They comprise two N-terminal CUB domains (for complement
C1r/C1s, Uegf, and Bmp1) each containing a binding site for
MBL, separated by an epidermal growth factor (EGF)-like do-
main, which together form an antiparallel dimer (Wallis and
Dodd, 2000). These are followed by two complement control
modules (CCP) and a C-terminal serine protease (SP) domain,
which control substrate recognition and catalysis (Dobo´ et al.,
2009; Harmat et al., 2004). As well as activating complement,
components participate in clearance of apoptotic cells (Botto
et al., 1998), coagulation (Gulla et al., 2010; Krarup et al.,
2007), inflammation (Megyeri et al., 2009), and development
(Rooryck et al., 2011).
The lectin pathway of complement is similar to the classical
pathway, where C1q substitutes for MBL and homologous
proteases C1r and C1s replace MASPs (Wallis et al., 2010).
Complexes have similar architectures, associate through analo-
gous Ca2+-dependent interactions, and activate complement
via comparable mechanisms. Knowledge of the molecular basis
of activation is lacking, primarily because the way in which
components bind to each other is not known. To address this
shortfall, we have determined the structure of components of
the activating complex of the lectin pathway. The data explain
how binding partners assemble and elucidate the essential
role of Ca2+, revealing major differences from previous predic-
tions. Moreover, by combining the various structures that are
now available, it is possible to develop a general mechanism
for the physical changes in complexes that lead to complement
activation.
RESULTS
Structural and Biochemical Characterization of Binding
Partners
Despite intensive efforts over many years, attempts to determine
a high-resolution structure of a lectin or classical pathway43, November 9, 2011 ª2011 Elsevier Ltd All rights reserved 1635
Figure 1. MASP-1 CUB2 binding to Ca2+ and MBL
(A) Gel filtration (Superdex 200; 16 mm/600 mm) of MASP-1 CUB2 (0.2 mg)
in the presence and absence of 2 mM CaCl2.
(B) Isothermal titration calorimetry of Ca2+ binding to MASP-1 CUB2. A
representative experiment showing the energy released as CaCl2 is added to
the CUB2 domain (black) or buffer (gray). KD = 0.49 ± 0.01mMandDH=4.6 ±
0.6 kcal/mol in two independent experiments.
(C) Binding of MASP-1 CUB2 toMBL using surface plasmon resonance. CUB2
was injected at 20, 10, 5, and 2.5 mM and data were fitted to a 1:1 binding
model in which kon = 131 ± 13 M
1s1 and koff = 3.5 ± 0.3 3 10
3 s1 in two
independent experiments.
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1636 Structure 19, 1635–1643, November 9, 2011 ª2011 Elsevier Ltdcomplex have been unsuccessful, probably as a result of the
heterogeneity of components and their intrinsic flexibility. We
therefore focused on the smallest binding unit common to both
pathways: a CUB domain bound to a collagen-like stem. The
CUB2 domain of MASP-1/-3 (subsequently called MASP-1
CUB2) was expressed in Escherichia coli, refolded, and purified.
It eluted significantly later from a gel filtration column in presence
of Ca2+, both confirming Ca2+ binding and suggesting that the
bound form is more compact (Figure 1A). Isothermal titration
calorimetry yielded a KD of 0.5 mM for Ca
2+, consistent with
the site being mostly occupied under physiological conditions
in plasma, where the Ca2+ concentration is typically 2.5 mM
(Figure 1B) (Hurwitz, 1996). As anticipated, binding to MBL
was weak with an apparent KD of 27 mM (Figure 1C) compared
to full-size MASP-1 (KD 10 nM), where multiple interactions
contribute simultaneously (Chen and Wallis, 2001; Girija et al.,
2007).
We determined the crystal structure of the CUB2 domain in
three different conditions (Table 1). It is a b sandwich comprising
nine b strands, b2–b10, linked by loops L1–L9, and with inter-
chain disulfide bonds connecting loop L1 to strand b4 and
loop L5 to loop L7. Ca2+ is bound at one end, sandwiched
between loops L5 and L9 (Figure 2A). Six coordinating ligands
to the Ca2+ are arranged in a tetragonal bipyramid via the side
chains of Glu216, Asp226, Asp263, the main chain of Ser265
and two water molecules (Figure 3B). Ca2+ stabilizes loops L5
and L9 in comparison with the apo-structure of MASP-2 (Fein-
berg et al., 2003), in which much of loop L5 is disordered,
accounting for the more compact structure shown by gel filtra-
tion (Figure 2C).
We designed two collagen-like peptides containing the
binding motif of MBL at the center. Peptide 1 bound to MASP-
1 CUB2 with a KD of 125 mM (Figure 1D). The crystal structure
of both uncomplexed peptides was determined and peptide 1
is shown in Figure 2B. It is a straight right-handed collagen-like
triple helix, 12 A˚ in diameter with the chains having a char-
acteristic stagger, such that each residue has a unique chemical
environment. The side chains of Lys46 and Leu47 point into the
solvent with Lys46 of the leading chain showing nice density up
to the Cε atom, as a consequence of stacking against Hyp44 of
the trailing chain. In contrast, the side chains of Lys46 in the other
two chains do not make intrachain contacts and are relatively
poorly resolved.
Structure of the Lectin Pathway Complex
Crystals of MASP-1 CUB2 in complex with peptide 1were grown
in the presence of Ca2+ and diffracted to 1.8 A˚ resolution (Fig-
ure 3A and Table 1). The MASP binds to two of the three
OGKLGP motifs in the collagen peptide (Figure 3D) with the
leading and trailing chains accounting for 56% and 44% of the
buried interface, respectively; the middle chain does not contact
theMASP (Table 2). The side chain of Lys46 of the leading strand
penetrates the MASP to contact three of the residues that also
coordinate the Ca2+, the carboxylate groups of Glu216 and
Asp263 and the hydroxyl group of Ser265 (Figure 3C), which(D) Binding of peptide 1 to MASP-1 CUB2 using surface plasmon resonance.
Error bars represent the difference between duplicate measurements. The KD
was 125 ± 17 mM in two separate experiments.
All rights reserved
Table 1. Data Collection and Refinement Statistics
CUB2-Form 1 Peptide1 Peptide2 Complex CUB2-Form 3 CUB2-Form 2
CUB2/
Methylamine
CUB2/
Ethylamine
Data collection
Space group P41212 C2 C2 P21212 C2 P213 P213 P213
Cell dimensions
a, b, c (A˚) 36.7,
36.7,
168.6
85.3,
23.7,
26.9
84.9,
23.4,
25.8
61.2,
52.6,
57.8
111.7,
64.7,
52.4
100.5,
100.5,
100.5
100.6,
100.6,
100.6
100.5,
100.5,
100.5
a, b, g () 90.0,
90.0,
90.0
90.0,
94.1,
90.0
90.0,
94.0,
90.0
90.0,
90.0,
90.0
90.0,
92.3,
90.0
90.0,
90.0,
90.0
90.0,
90.0,
90.0
90.0,
90.0,
90.0
Resolution (A˚)a 30–1.5
(1.6–1.5)
50–1.5
(1.58–1.5)
50–1.5
(1.59–1.5)
30–1.8
(1.9–1.8)
50–2.75
(2.9–2.75)
50–1.5
(1.59–1.5)
50–1.7
(1.8–1.7)
30–1.45
(1.54–1.45)
Rsym or Rmerge 3.4 (16.9) 9.3 (35.9) 4.5 (15.2) 6.1 (30.7) 17.1 (36.5) 7.6 (33.1) 8.7 (32.2) 7.9 (30.6)
I/sI 34.7 (9.3) 4.0 (2.0) 25.9 (10.2) 25.7 (5.4) 5.8 (2.7) 18.5 (4.4) 18.0 (4.8) 15.7 (4.9)
Completeness (%) 99.5 (99.2) 99.4 (99.4) 98.8 (96.9) 99.6 (99.3) 83.6 (78.6) 99.6 (99.7) 99.9 (100) 99.1 (96.3)
Redundancy 7.1 (7.2) 2.9 (2.8) 3.0 (3.0) 4.3 (4.4) 2.3 (2.1) 4.9 (4.9) 5.1 (5.1) 4.1 (4.0)
Refinement
Resolution (A˚) 27.7–1.5 42.5–1.5 22.7–1.5 26.4–1.8 39.0–2.75 41.0–1.5 45.0–1.70 29.0–1.45
Reflections (n) 18,424 8296 7884 16,865 413 51,198 35,529 56,325
Rwork/ Rfree 13.3/17.7 14.1/19.0 11.5/19.2 19.8/25.2 21.1/26.6 11.7/14.9 11.9/15.6 12.5/15.6
Atoms (n) 1106 613 567 1609 2693 2214 2159 2207
Protein 933 515 473 1424 2688 1943 1906 1906
Ligand/ion 2 1 3 20 22 23
Water 171 98 94 184 2 251 231 278
B-factors 19.6 12.6 10.7 24.1 40.0 17.7 16.3 14.5
Protein 16.8 10.8 9.2 23.0 40.0 15.9 14.8 12.3
Ligand/ion 15.1 13.9 40.0 13.2 14.2 13.2
Water 34.8 22.0 18.3 33.2 40.0 32.0 29.1 29.6
Rmsd
Bond lengths (A˚) 0.024 0.026 0.024 0.023 0.008 0.034 0.029 0.029
Bond angles () 2.05 2.78 2.65 2.19 1.27 2.40 2.14 2.24
PDB ID 3POE 3PON 3POD 3POB 3POG 3POF 3POI 3POJ
PDB, Protein Data Bank; Rmsd, root-mean-square deviation.
aHighest resolution shell is shown in parenthesis.
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Structure of the MBL-MASP Complexchange little upon collagen binding. The Ca2+ thus serves at
least two roles: first it stabilizes the binding loops L5 and L9,
and second, it coordinates the specific arrangement of acidic
residues that contact Lys46 of MBL. This structure, there-
fore, provides a clear rationale for the Ca2+-dependence of
binding, a feature common to all lectin and classical pathway
complexes.
Unexpectedly, the relative orientations of MBL and MASP
are different from previous predictions, which were based
primarily on mutagenesis of human MASP-1 (Teillet et al.,
2008). In particular MBL is inverted relative to previous models
and the collagen-like stem follows a different path across the
MASP (Figure S2). Binding is stabilized by a combination of
hydrogen bonds and hydrophobic contacts. In particular,
Hyp44 of the trailing chain, forms two important water-mediated
hydrogen bonds to the carbonyl group of Asp217 and the
carboxylate of Asp216 (Figure 3D), probably accounting for the
unique conformation observed in the crystal structure. TheseStructure 19, 1635–16interactions would not be possible if Lys46 of the middle or
trailing strandwere to sit in the binding pocket, because a leucine
residue would occupy the position of the hydroxyproline. Tyr225
of the MASP forms extensive hydrophobic interactions at the
binding interface and its hydroxyl group forms a hydrogen
bond with the backbone carbonyl of Leu47 of the leading chain
of the collagen. His218 also participates in the hydrogen-
bonding network, forming backbone contacts to the carbonyl
of Gly45 of the trailing chain and the amide of Glu220 of the
MASP. The latter interaction probably stabilizes the conforma-
tion of loop L5, which remains in close proximity to the collagen,
thereby reducing solvent accessibility to the binding interface.
The side chain of Glu220 in loop L5 is sandwiched between
the side chain of Lys46 and the amide of Leu47 of the trailing
chain and is partially buried at the interface (Figure 3D). Overall
binding buries just 326 A˚2 of solvent-accessible collagen surface
and 305 A˚2 of the MASP1, which is small for a protein/protein
complex and smaller than the handful of protein/collagen43, November 9, 2011 ª2011 Elsevier Ltd All rights reserved 1637
Figure 2. Structures of MASP-1 CUB2 and the
Collagen-Like Peptide from MBL
(A) Structure of unbound MASP-1 CUB2 (crystal form 1,
PDB: 3POE). Secondary structural elements are indicated,
and the Ca2+ is shown in violet. Numbering is based on the
mature MASP polypeptide.
(B) Structure of the unbound collagen-like peptide with the
leading, middle and trailing strands in white, black, and
gray, respectively (peptide 1, PDB 3PON). The sequence
of the peptide is shown below the structure, to illustrate
the stagger between each chain. Numbering is based on
the mature rat MBL polypeptide. Residues involved in
MASP binding are highlighted in red. Lys46 and Leu47 of
the leading chain are indicated by arrows.
(C) Comparison of the Ca2+-boundMASP-1 CUB2 domain
(white) with the apo-MASP-2 CUB2 domain (green). In the
apo-structure, loop L5 and some of the side chains in
Loop L9 (MASP2 equivalents of Asp263 and Asn264) are
absent in the density map likely due to flexibility, sug-
gesting that Ca2+ stabilizes the CUB fold by reducing
flexibility in loops L5 and L9. See also Figure S1.
Structure
Structure of the MBL-MASP Complexcomplexes for which structures are available (Emsley et al.,
2000; Zong et al., 2005; Hohenester et al., 2008; Carafoli et al.,
2009).
The structure of the CUB-collagen complex explains previous
data which show: the importance of Ca2+, and the role of the
essential lysine residue in MBL and ficolins (Girija et al., 2007;1638 Structure 19, 1635–1643, November 9, 2011 ª2011 Elsevier Ltd All rights reserveWallis et al., 2004). It also explains the signifi-
cance of residues tested by mutagenesis of
human MASP-1 (Teillet et al., 2008). For
example, the mutation Tyr225Ala completely
disrupted binding to H-ficolin and reduced
binding to MBL and L-ficolin significantly,
whereas His218Ala reduced binding to all
three proteins. Interestingly, Ser265Ala had
relatively little effect, showing that loss of the
hydrogen bond between Ser265 and Lys46
can be partially tolerated, presumably because
the remaining two salt-bridges mediated by
Glu216 and Asp263 are preserved.
Steric factors probably play an important role
in determining the relative orientations of MBL
and MASP. In the binding orientation, His218
and Tyr225 occupy a groove in the collagen
formed from residues that make up the MASP-
binding motif (OGKLGP) and make hydrogen
bonds with the peptide backbone. Because
the binding motif is present in all MBLs, ficolins,
CL-K1 and C1q (Figure S2), this groove is likely
to be a common feature. By contrast, residues
forming the adjacent groove (that would be
occupied in the alternative orientation) are vari-
able in different family members and often
bulky, so would exclude the MASP (Figure S2).
For example, in human and rat MBLs, leucine
and glutamine residues would block access to
His218 and Tyr225.
Comparison of the structure of the complex
with structures of the CUB2 domain in theabsence of the collagen (CUB-Forms 1, 2A, and B; Table 1)
reveals differences in the position of loop L5 (Figure 4A), con-
sistent with significant but limited flexibility in the unbound
MASP. In particular, the positions of Tyr225, His218, and
Glu220, diverge by several angstroms. By contrast, these resi-
dues are essentially fixed in all complexes (MASP1 bound tod
Figure 3. Structure of the Ca2+-Dependent MBL/MASP Complex
(A) Crystal structure of MASP-1 CUB2 (green) bound to the MBL collagen-like
peptide 1 (white) (PDB: 3POB). The CUB2 domain is located mainly on the
outside of the cone created by the MBL subunits (left).
(B) The Ca2+-binding site of the unbound CUB2 domain, showing the six
coordinating ligands arranged in a tetragonal bipyramid. The Ca2+ is shown in
violet, water molecules as red spheres, and ionic and electrostatic bonds by
dotted lines.
(C) The same view of the CUB domain in the complex, showing the interaction
with Lys46 of MBL.
(D) Close-up of the MBL/MASP interface. The electrostatic potential of the
collagen is shown on a semitransparent surface representation with key
structural elements represented as ball and sticks; binding residues of CUB2
(green) are shown as cylinders. Residue numbers of the MBL leading and
trailing strands (with an apostrophe) are shown. See also Figure S2.
Table 2. Surface area (A˚2) of MBL buried upon complex formation
MBL residue Leading Trailing
Hyp44 0 54.2
Gly45 0 8.6
Lys46 106.5 32.2
Leu47 9.7 48.2
Gly48 0.1 0
Pro49 65.0 0
Hyp50 1.9 0
The total buried area is 326.4 A˚2. MBL, mannan-binding lectin.
Structure
Structure of the MBL-MASP Complexcollagen, methylamine, ethylamine or the autoinhibited form;
Table 1 and see below), because of packing of the collagen
against Tyr225. Thus, the collagen locks the binding loops of
the MASP against the collagen-like stem. Otherwise, there is
little conformational change to the CUB or the collagen stem
on association.
A Conserved Mode of Ca2+-Dependent Binding
in the Classical and Lectin Pathways
The mode of binding described here is likely to be the same in all
activating complexes of the lectin and classical pathways. Lys46
of MBL is central to all interactions and binding residues are
strictly conserved in the CUB2 domains of MASP-2 and C1r
(Figures 4C and 4D; Figure S3). However, His218 and Tyr225
are substituted by alanine and leucine in C1s (Figure 4E), whichStructure 19, 1635–16does not bind to C1q (Phillips et al., 2009). Superimposition of
MASP-1 CUB1 and CUB2 structures further demonstrates the
similarity of the collagen-binding sites, whereby the side chains
of the Ca2+-coordinating residues Glu49, Asp102, and Ser104
substitute for Glu216, Asp263, and Ser265, respectively (Fig-
ure 4B; Figure S3). In addition, Tyr56 substitutes for Tyr225,
but the histidine in loop L5 is missing. Instead, Phe103 of loop
L9 and Tyr52 of loop L5 probably participate in binding to dictate
the orientation of the collagen-like stem, consistent with
previous mutagenesis data (Teillet et al., 2008).
The central features of the MBL-MASP structure are also
remarkably similar to binding between vitamin B12-bound gastric
intrinsic factor and cubilin (another CUB-containing protein),
revealing a common mechanism for Ca2+-dependent CUB inter-
actions (Andersen et al., 2010). In each case, binding is multiva-
lent involving the interaction of a basic side chain to residues
coordinating a Ca2+ within the CUB, with neighboring loops
making additional contributions. The propensity of Ca2+-binding
CUB domains to bind in this way is further demonstrated in
a crystal structure of the autoinhibited CUB domain of MASP-1
(CUB2-Form 3), in which a lysine side chain from each of the
three domains present in the asymmetric unit penetrates into
the binding pocket of its adjacent partner, mimicking the natural
collagen/CUB interaction (Figure S3).
Structure Guided Inhibition of MASP Interactions
The binding pocket of the MASP represents an attractive poten-
tial target for small molecule inhibitors of complement activation
by preventing assembly of activating complexes. To verify this
concept we tested the inhibitory activities of small amines using
a lectin pathway-specific assay. Remarkably, lysine inhibited
complement activation in both human (Figure 5A) and mouse
serum (Figure S4) with IC50 values of 30 mM, whereas other
amino acids (alanine, serine, and threonine) had little effect, at
concentrations up to 400 mM. Lysine also inhibited binding
between MBL and full-length MASP-1 (IC50 of 50 mM); Fig-
ure S4), suggesting that complement inhibition was caused by
dissociation of MBL/MASP complexes in serum. Inhibition of
binding was not due to increasing ionic strength because addi-
tion of extra NaCl (up to 400 mM) above physiological ionic
strength had little effect (Figure S4). To confirm the mechanism
of inhibition, we cocrystallized the CUB2 domain with ethylamine
and methylamine, which also inhibited MBL binding. In the
resulting structures, both inhibitors occupy the lysine-binding
pocket of the MASP, forming equivalent contacts to Glu216,43, November 9, 2011 ª2011 Elsevier Ltd All rights reserved 1639
Figure 4. Conserved Mechanism of CUB-Collagen
Interactions in the Lectin and Classical Pathways
of Complement
(A) Comparison of collagen-bound MASP-1 CUB2 with
four unbound structures (from crystal forms 1, 2A, 2B, and
3). Ca2+ and Ca2+-coordinating residues are in equivalent
positions. Different conformations of Loop L5, and Tyr225
in particular, reflect a significant flexibility.
(B) Superimposition of rat MASP-1 CUB2 and human
MASP-1 CUB1 (PDB: 3DEM) (Teillet et al., 2008). The
lysine-binding pocket is conserved reflecting a common
mode of binding. Ca2+-coordinating residues occupy
equivalent positions, whereas differences in the binding
loops L5 and L9 probably dictate the orientation of the
collagen-like domain.
(C–E) Same view of the MBL/MASP complex in which:
(C) binding residues are shown in red; (D) identical
and conserved substitutions in human MASP-1, MASP-2,
and C1r are shown in purple and yellow, respectively, and
(E) binding residues that are the same in C1s are in
red and those that are different are in blue. See also
Figure S3.
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Structure of the MBL-MASP ComplexAsp263, and Ser265, and packing against Tyr225 (Figure 5B;
Figure S4), thus blocking the binding site.
DISCUSSION
Implications for Complement Activation
A variety of models have been proposed to explain the mecha-
nism of complement activation. However, lack of structural infor-
mation on the interactions between components has prevented
a detailed description of the physical changes. Combining our
MBL/MASP complex with the structure of the CUB1-EGF-
CUB2 dimer of human or rat MASP (Feinberg et al., 2003; Teillet
et al., 2008), reveals that the MASP domains take the form of the
cross-bar of an uppercase letter ‘‘A,’’ with each CUB2 domain
holding a collagen-like stem to form the sides. By bridging
separate stems, the MASP is receptive to changes imparted
following engagement of a pathogen by MBL. However, the
unexpected orientation of MBL relative to the MASP means
that rather than converging at the N-terminus as predicted in
previous models, instead the collagenous stems crossover and
extend beyond the point of intersection (Figure 6A). Clearly,
this would not be possible in a MBL/MASP complex, because
the stems are bound together at the base. Thus, one or both
components must change conformation when they associate,
imparting strain to the resulting zymogen complex (Figure 6B).
Given the rigidity of the stems, binding probably leads to distor-
tion of the MASP, via flexion of the EGF-CUB2 junction. This
junction is likely to be flexible because it is susceptible to prote-
olysis (Wallis and Dodd, 2000) and the domain interface is small,
unlike the CUB1-EGF junction, which is fixed through extensive
hydrophobic packing (Feinberg et al., 2003; Teillet et al., 2008).
When MBL engages with a pathogen, release of the tension
would lead to extension of the EGF-CUB2 junction as the stems1640 Structure 19, 1635–1643, November 9, 2011 ª2011 Elsevier Ltd All rights reservesplay apart, pulling the SP domains together
to allow reciprocal activation (Figure 6C). This
simplemodel only requires changes to the angle
between the stems of MBL and flexion/exten-sion of the EGF-CUB2 junction of the MASP; the MBL/MASP
contacts remain fixed. Importantly, it is compatible with kinetic
and biochemical data, which also suggest that the MASP
becomes primed for activation when it binds to MBL (Chen
and Wallis, 2004; Venkatraman Girija et al., 2010).
The MBL/MASP Interface as a Target for Inhibitors
of Complement Activation
Inhibition of the lectin pathway has potential for the treatment
of complement-dependent disorders and ischemia-reperfusion
injury following cardiac arrest or stroke (Schwaeble et al.,
2011). The C1 complex is also an important drug target because
of its pathogenic role in various neurodegenerative disorders
including Alzheimer’s disease (Tenner and Fonseca, 2006).
The structural insight described here provides a starting point
for the design of such therapeutics. Although the affinities of
the small amine inhibitors identified here is low, high-affinity
compounds can potentially be developed using a fragment-
based approach, in which two or more small compounds are
combined (Murray and Blundell, 2010). Notably, although the
binding site itself is highly conserved, it is surrounded by variable
residues which would allow specificity to be introduced into
larger inhibitors (Figure 5C). Such inhibitors would block com-
plement at its earliest stage, before amplification, and would
not compromise other immunological processes.
EXPERIMENTAL PROCEDURES
Production and Refolding of the MASP-1 CUB2 Domain
The cDNA encoding rat MASP-1 CUB2 (E165-A277) was cloned into pET28A
(Novagen) and transformed into E. coli BL21 DE3. Production was induced by
addition of IPTG (1mM) at an OD595 of 0.8 in 23YTmedium at 37
C. After 4 hr,
cells were lysed by sonication in Bugbuster reagent (40 ml/L of culture;
Novagen) containing a protease inhibitor cocktail (1 tablet/40 ml of cultured
Figure 5. Inhibition of Complement Activation by Small Amines
(A) Inhibition of the lectin pathway of complement activation by lysine measured by deposition of the membrane-attack complex. Data are expressed relative
to the activation in the absence of lysine. Error bars represent the difference between duplicate measurements. The IC50 from three independent experiments
was 25 ± 3 mM.
(B and C) Structure of the lysine-binding pocket of MASP-1 CUB2 bound to ethylamine; (C) Conserved residues in human MASP-1, MASP-2, and C1r (purple
for identical and yellow for similar) at the binding interface are surrounded by patches of nonconserved residues (white; contoured by dotted lines). See also
Figure S4.
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Structure of the MBL-MASP Complexsuspension; Roche). Inclusion bodies were washed twice with 1:10 diluted
Bugbuster mix, 2 M urea in 50 mM Tris/HCl pH 8.0 containing 0.5 M NaCl
and 1 mM EDTA and were solubilized to a final concentration of 2 mg/ml in
8M urea in 50 mM Tris/HCl pH 8.0, containing 5 mM DTT. The CUB domain
was refolded by drop dilution into 50 mM Tris/HCl, pH 8.5, containing
240 mM NaCl, 10 mM KCl, 2 mM MgCl2, 2 mM CaCl2, 0.4 M sucrose, and
1 mM DTT so that the final protein concentration was 0.1 mg/ml. After
3 days at 4C, the sample was bound to a Q-Sepharose column (20 mL)
equilibrated with 25 mM Tris/HCl at pH 8.0, containing 25 mMNaCl and eluted
using a gradient of NaCl (25 mM to 1 M over 40 ml). It was further purified by
gel filtration (16/60 Superdex 75; GE Healthcare) in 10 mM Tris buffer (pH
7.5) containing 10 mM NaCl and 2 mM CaCl2.
Proteins and Peptides
Rat MBL-A (referred to as MBL) and MASP-1ent (referred to as MASP-1),
a modified form of MASP-1 that cannot autoactivate were produced and puri-
fied as described previously (Chen and Wallis, 2004; Wallis and Drickamer,
1999). Two collagen peptides were made by Pepceuticals Ltd. Peptide 1 is
Ac(GPO)4-GKL-(GPO)4NH2 and peptide 2 is Ac(GPO)3-GKL-(GPO)4NH2.
Crystallization and Structure Determination
All crystals were grown using the sitting-dropmethod bymixing equal volumes
(1.2 + 1.2 mL) of protein and reservoir solution. They were transferred to reser-
voir solution containing 20% glycerol before cryoprotection in liquid nitrogen,
and were maintained at 100 K during data collection. Diffraction data were
collected at ESRF and Diamond Light Source and were processed with XDS
(Kabsch, 1993). Phases were determined by molecular replacement with
Phaser and models were optimized using cycles of manual refinement with
Coot and maximum likelihood refinement in Refmac5, part of the CCP4 soft-
ware suite (Collaborative Computational Project, 1994). For the complex,
CUB domain (5 mg/ml; 0.38 mM) containing a 1.5-fold molar excess of trimeric
peptide was mixed with 28% PEG 8000, 50 mM Tris/HCl, pH 8.0, and 4 mM
CaCl2. Phases were determined using structures of the free components as
search models.
The CUB2 domain alone was crystallized in three different conditions to
give different crystal forms (Table 1). Reservoir solutions were: (1), 24% PEG
8K in 50mMTris/HCl, pH 9.0 containing 20mMCaCl2; (2), 1.5M lithium sulfate
in 100 mM Tris, pH 8.5; and (3), 24% PEG 8 K in 50 mM Tris/HCl, pH 9.0
containing 200mMMgCl2. The initial structure (crystal form 1) was determined
using the human MASP-1 CUB2 module as a search model (Protein Data
Bank [PDB] ID: 3DEM) (Teillet et al., 2008), and was refined to 1.5 A˚ resolution
(Table 1). The identity of the Ca2+ was verified by its anomalous signal using
CuKa radiations from an in-house X ray source. We found a second Ca2+ ion
in the anomalous signal coordinated by Ser190, Glu192, and four water mole-
cules. This region of the protein is usually at the interface with the EGF module
in the full-length MASP, which would not permit Ca2+ binding, so its presence
is likely due to the high concentration of Ca2+ in the crystallization buffer.Structure 19, 1635–16Crystal form 2 contained two CUB molecules in the asymmetric unit (forms
2A and 2B; Table 1). Similar crystallization conditions were used for the
complexes with methylamine, ethylamine, and lysine. In each case, only one
conformation of CUB2 was seen bound to the amine. There were three mole-
cules in the asymmetric unit of crystal form 3, called the autoinhibited form,
which were almost identical (Table 1). Complexes of CUB2 bound to ethyl-
amine, methylamine, and lysine were crystallized in buffer condition 2, supple-
mented with 1 M amine (Sigma). Although crystals grew in the presence lysine
and novel density was observed in the binding pocket, lysine was not resolved
in the resulting structure, probably reflecting multiple binding conformations.
Both collagen peptides were crystallized using a reservoir solution of 1.6 M
ammonium sulfate in 100 mMMES, pH 6.0, but yielded different crystal forms.
Crystals of collagen peptide 1 and 2 each diffracted to 1.5 A˚ resolution and the
phases were determined by molecular replacement using the Gly-Pro-Hyp
collagen peptide structure as a search model (PDB ID: 1CAG) (Bella et al.,
1994). The C-terminal end of peptide 1 of the trailing chain is not well resolved
and shows higher temperature factor due to the absence of neighboring
chains.
Gel Filtration
Gel filtration was carried out on a 16/60 Superdex 200 column (GE Healthcare)
in 50 mM Tris/HCl pH 7.4, containing 150 mM NaCl at a flow rate of 1 ml/min.
Isothermal Titration Calorimetry
The CUB2 domain (114 mM) pretreated by dialysis to remove Ca2+ was titrated
with freshly prepared 2 mM CaCl2 in the same batch of assay buffer in the
cell of a VP-isothermal titration calorimeter (Microcal) equilibrated at 25C.
Data were fitted to a 1:1 binding model using the Origin software supplied.
Binding was measured under low ‘‘c-value’’ conditions (where the concentra-
tion of the protein in the cell is lower than that of the KD). The stoichiometry was
fixed at 1 (based on the crystal structure) and the KA and DH variables were
allowed to float.
Surface Plasmon Resonance
MBL (0.025 mg/ml) was immobilized onto the surface of a GLM sensor chip
(BioRad; 10,000 response units) at pH 4.5, using amine-coupling chemistry.
Binding to CUB2 was measured using a ProteOn XPR36 (BioRad) in 10 mM
Tris/HCl pH 7.4, containing 140 mM NaCl, 5 mM Ca2+, and 0.005% Tween-
20 at 25C, and at a flow rate of 25 mL/min. For inhibition assays, MBL was
immobilized on to a CM-5 sensor chip (GE Healthcare; 14,000 response
units) and binding was measured using a Biacore 2000 (GE Healthcare).
MASP-1 (100 nM) was premixedwith inhibitor and flowed over the chip surface
at a rate of 5 mL/min at 25C for 10 min. Changes in response units caused by
differences in sample composition were subtracted from all data. MASP-1
CUB2 was immobilized on to the chip at pH 4.0 (1000–2000 response units),
in the same way as MBL. Binding to peptide 1 was measured at 20C using
a flow rate of 5 ml/min.43, November 9, 2011 ª2011 Elsevier Ltd All rights reserved 1641
Figure 6. Structural Basis of Complement Activation in the Lectin
Pathway
(A) Superimposition of the structures of the MBL/MASP-1 complex with the
human CUB1-EGF-CUB2 (PDB: 3DEM) and extension of the collagen-like
stems to their full-length (59 residues) shows that the stems crossover, which
is not possible in intact MBL.
(B) In the zymogen complex, MBL and/or MASPmust undergo conformational
changes on binding. The simplest way is through flexion of the EGF-CUB2
junction of the MASP, creating a ‘‘spring-loaded’’ structure.
(C) Activation of the complex occurs upon binding to a pathogen. Release of
the strain causes the stems to splay apart and pulls the SP domains of the
MASP into alignment to allow reciprocal cleavage and activation. In thismodel,
only the angle between collagen-like stems (a) and flexion/extension of the
EGF-CUB2 junction is necessary for activation; the MBL/MASP contacts are
fixed.
Structure
Structure of the MBL-MASP ComplexComplement Activation Assays
Lectin pathway specific complement activation in human serum was
measured using the Wieslab MBL pathway kit (Euro-Diagnostica). The lectin
pathway is functional, even under conditions of high ionic strength (1 M
NaCl) (Petersen et al., 2001).
Complement activation in mouse serum was measured by deposition of
complement component C3c. Nunc MaxiSorb microtiter plates were coated
with 2 ug of mannan per well in 100 mM sodium bicarbonate buffer, pH 9.6.
After overnight incubation at 4C, wells were blocked with 0.1% bovine serum
albumin in binding buffer (10 mM Tris/HCl, 140 mM NaCl, pH 7.4) for 2 hr
at room temperature. The wells were then washed three times with binding
buffer containing 0.05% Tween-20 and 5 mM CaCl2. Mouse serum diluted
1:100 in 4 mM sodium barbitone buffer, pH 7.4, containing 145 mM NaCl,
2 mM CaCl2, 1 mM MgCl2, containing inhibitor was added to the plates
and incubated overnight at 4C. After three additional washes, bound C3c
was detected using rabbit anti-C3c antibody (Dako) and alkaline phosphatase
conjugated goat anti-rabbit IgG (Sigma) using Sigma FAST p-nitrophenyl
phosphate substrate (Sigma).1642 Structure 19, 1635–1643, November 9, 2011 ª2011 Elsevier LtdACCESSION NUMBERS
Coordinates have been deposited in the Protein Data Base with accession
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